About Contact Us Careers

Congenital Anomalies Treatment Market Size & Share, by Type of Treatment (Surgical Intervention, Pharmacological Treatment, Gene Therapy, Physical Therapy, Supportive Care); Therapy Type; End user; Diagnostic Method; Product Type - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2026-2035

  • Report ID: 2702
  • Published Date: Oct 06, 2025
  • Report Format: PDF, PPT

Congenital Anomalies Treatment Market Outlook:

Congenital Anomalies Treatment Market size is valued at USD 179.5 million in 2025 and is projected to reach USD 283.2 million by the end of 2035, rising at a CAGR of 5.2% during the forecast period, i.e., 2026‑2035. In 2026, the industry size of congenital anomalies treatment is estimated at USD 188.8 million.

The global patient pool for the congenital anomalies treatment market is growing due to birth rates in relatively lower-income countries increasing and diagnostic facilities improving in higher-income settings. According to a report by the World Health Organization in February 2023, on average, around 240,000 newborns die within a span of 28 days due to congenital disorders, with more than 170,000 deaths occurring between 1 month and 5 years of age. This very burden has caused demand for interventions to experience upward pressure during the very early stages, particularly in prenatal screening and corrective treatments. Supply chains remain dependent on very high-precision imports of APIs, diagnostic reagents, and implantable devices, especially in developing markets.

Key components of the supply chains supporting the market consist of active pharmaceutical ingredients (API) for prenatal and postnatal diagnostics, surgical devices for corrective interventions, and specialized nutritional/therapeutic products. Furthermore, emerging trends offer proxy awareness about the producer price index (PPI) and consumer price index (CPI) as tracked by the U.S. Bureau of Labor Statistics (BLS). As per a report by the U.S. Bureau of Labor Statistics (BLS) in September 2025, in May 2025, the producer price index for surgical and medical instruments was at 157.8. The upward trend directly determines the structure of costs for the market and the downstream pricing strategies and investment decisions.

PPI Commodity Indexes in Healthcare and Their Relative Importance as of December 2022

Index title

Relative Importance in Final Demand, December 2022 (%)

Relative Importance in Health Care Services, December 2022 (%)

Health care services

16.6

100.0

Outpatient care

10.6

63.6

Physician care

4.0

23.7

Medical laboratory and diagnostic imaging center care

0.3

2.4

Home health and hospice care

0.9

5.3

Hospital outpatient care

4.3

25.4

Dental Care

1.1

6.7

Inpatient Care

6.0

35.8

Hospital inpatient care

4.5

26.9

Nursing home care

1.2

7.3

Intellectual and developmental disability center care

0.3

1.5

Sales of blood and blood products, organs, and tissues

0.1

0.6

Source: U.S. BLS

Congenital Anomalies Treatment Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Government spending on healthcare & advancements in healthcare quality improvement: Governments are keen on expanding their healthcare budgets to mitigate rising cases in the congenital anomaly treatment market. As per a report by the World Health Organization in December 2023, there was a new high level of spending on health at USD 9.8 trillion or 10.3% of worldwide gross domestic product (GDP) in the previous 4 years. Moreover, Low-income countries shared 0.24% of the global health spending, even though they had an 8% population share of the world. The increasing financial investment is anticipated to be the driver for significant growth in the market, with growing funds to be the fuel for advancements in diagnostics, therapeutics, and surgery across the world.
  • Unmet needs in emerging markets & company innovations: The gap between the demand for healthcare services and the available supply creates important opportunities for both established companies and new businesses to grow in the congenital anomalies treatment market. Among emerging technologies, telemedicine has taken center stage as it has significantly enhanced consultation processes. As per a report by NLM in October 2023, this innovation becomes much more critical considering nearly 50% of birth defects remain without any well-defined etiology, making diagnosis and timely intervention difficult. However, the known etiologic factors are parental chromosomal abnormalities (2 to 4%), anatomical and endocrine conditions (10 to 27%), and antiphospholipid antibody syndrome (17 to 20%), requiring the initial input of a specialist, oftentimes difficult to obtain in low-resource settings.
  • Rising Prevalence of Birth Defects and Improved Regional Reporting Systems: For the market, an increasing number of reported congenital anomalies accounts significantly toward the growth of the market. As per a report by the World Health Organization in 2025, births were recorded in over 150 hospitals 2025 across the region, with more than 3,000 cases of birth defects recorded. Therefore, growing awareness about congenital anomalies and reporting them highlights the magnitude of the problem  and the need for early diagnosis, intervention, and specialized treatment. Better healthcare infrastructure and stronger birth defect surveillance systems lead to better opportunities for early detection and improved management of congenital anomalies. As awareness grows amongst the medical professionals and parents, the demand for surgical interventions, therapeutic devices, and ongoing medical care will also grow.

Risk of Major Congenital Malformations Associated with Select Drugs (2025)

Drug

(Livebirths/MCM %) (major congenital malformations)

Adjusted OR

Adjusted OR

Butylscopolamine

72/6 (8.3%)

2.92 (1.26-6.79)

1.79 (0.61-5.25)

Budesonide

89/10 (11.2%)

3.35 (1.68-6.69)

2.38 (0.82-6.92)

Liraglutide

55/8 (14.5%)

3.52 (1.59-7.82)

0.74 (0.20-2.70)

Insulin glargine

460/45 (9.8%)

2.71 (1.98-3.72)

0.93 (0.39-2.24)

Insulin (human)

601/49 (8.2%)

2.59 (1.91-3.51)

0.61 (0.29-1.31)

Insulin (human)

1069/86 (8.0%)

2.53 (2.01-3.17)

0.81 (0.44-1.50)

Insulin aspart

1495/125 (8.4%)

2.43 (2.01-2.93)

1.34 (0.52-3.46)

Insulin detemir

473/35 (7.4)

2.12 (1.48-3.02)

1.09 (0.46-2.62)

Source: NLM

Challenges

  • Stringent Regulatory Approvals: The market growth and adoption are largely hindered by the rigorous approval and regulatory norms before drug and product launch in the congenital anomalies treatment market. The high cost of research, development & deployment has led to high CapEx requirements. Clinical trials, followed by strict approvals, are cost-intensive, making it a challenge for smaller players to gain a competitive edge. Furthermore, the approval process's time span being long can hold up the introduction of innovative treatments and affect market dynamism. The regulatory complexities lead to further costs for the end consumer, limiting accessibility and adoption in emerging markets.
  • Limited awareness and early diagnosis: The market is constrained due to a lack of general awareness about congenital defects among parents and, in some instances, even among healthcare providers, especially in a few resourcefully constrained settings. This often results in delayed diagnosis and treatment, thus decreasing intervention efficacy. In addition, poor access to more advanced diagnostic techniques and specialized medical establishments in rural or backward areas renders early detection and timely intervention impossible, thereby inhibiting market expansion and better patient outcomes.

Congenital Anomalies Treatment Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

5.2%

Base Year Market Size (2025)

USD 179.5 million

Forecast Year Market Size (2035)

USD 283.2 million

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Congenital Anomalies Treatment Market Segmentation:

End user Segment Analysis

The hospitals and clinics segment in the end user segment in the congenital anomalies treatment market is likely to dominate the market with a share of 43% in the forecast period. The growth is ascribed to the centralization of congenital anomaly expertise, emerging gene therapy capabilities, and advanced neonatal ICUs. As per a report by CMS in June 2025, the expenditures for physicians and clinical services rose by 7.4% to USD 978 billion, having registered only 4.6% GDP in 2022. The surge in expenditures is resulting in enhanced demand for specialized pediatric and surgical services in hospital settings. Furthermore, with the assurance of multidisciplinary care teams in hospitals for the integrated management of complex congenital conditions, treatment outcomes get better, thereby supporting the market growth of the market.

Type of Treatment Segment Analysis

The surgical intervention subsegment is expected to hold the highest market share in the type of treatment segment within the forecast period in the congenital anomalies treatment market. Procedures such as atrial septal defects and Tetralogy of Fallot are vital in mitigating congenital anomalies due to the high global birth incidence. In such complex cardiac procedures, the cannulation strategy needs to be carefully planned ahead of the case, with proper device selection. As per a report by NLM in November 2023, central cannulation (aortic/bicaval) is mostly preferred for cases weighing under 30 kg, a hybrid strategy is adopted for patients between 30 and 50 kg, and complete peripheral cannulation is generally used in cases exceeding 50 kg. This differentiated approach especially increases operative precision and patient safety in pediatric cardiac surgeries.

Diagnostic Method Segment Analysis

The prenatal screening sub-segment is expected to hold the highest market share in the diagnostic method segment within the forecast period in the congenital anomalies treatment market.  Growing awareness about early detection, increasing adoption of non-invasive prenatal testing (NIPT), and improvements in ultrasound technology, along with genetic testing, are driving this growth. There exist maternal health programs by the government's initiative on one hand, and key guidelines for routine prenatal care in both developed and emerging economies supporting this trend on the other. The early diagnosis achieved with prenatal screening promotes timely medical planning and intervention with significant improvement in neonatal outcomes.

Our in-depth analysis of the global market includes the following segments: 

Segment

Subsegments

Type of Treatment
  • Surgical Intervention
  • Pharmacological Treatment
  • Gene Therapy
  • Physical Therapy
  • Supportive Care

Therapy Type
  • Gene Therapy
  • Pharmacotherapy
  • Enzyme Replacement Therapy
  • Stem Cell Therapy
  • Surgical Therapy

End user
  • Hospitals and Clinics
    • Surgical Intervention
    • Pharmacological Treatment
    • Gene Therapy
    • Physical Therapy
    • Supportive Care
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Home Healthcare Settings
  • Research and Academic Institutes

Diagnostic Method
  • Prenatal Screening
    • Medical Devices
    • Biologics
    • Pharmaceuticals
    • Diagnostic Tools
    • Assistive Devices
  • Postnatal Screening
  • Genetic Testing
  • Imaging Techniques
  • Biomarker Analysis

Product Type
  • Medical Devices
  • Biologics
  • Pharmaceuticals
  • Diagnostic Tools
  • Assistive Devices
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Congenital Anomalies Treatment Market - Regional Analysis

North America Market Insights

North America market is expected to hold the highest market share of 39% by the end of 2035, largely due to the U.S. and Canada’s flourishing provincial initiatives to bridge the gaps between supply and demand. According to a report by CMS in December 2024, U.S. health care spending grew by 7.5% in 2023, reaching USD 4.9 trillion or USD 14,570 per capita. Health care expenditures thus amounted to 17.6 percent of the gross national product. This increase has witnessed thousands of patients gaining medical accessibility every year. The presence of renowned pharmaceutical and biotech companies also accelerated the development of modern therapies and diagnostics for congenital disorders.

The congenital anomalies treatment market in the U.S. is growing due to increasing healthcare investments and expanding access to specialist medical services. As per a report by CMS in June 2025, prescription drug spending rose by 11.4% in 2023, thus reaching approximately USD 449.7 billion. This growth rate exceeds the 7.8% increase recorded in 2022 and is due to increased utilization of advanced therapies. This increased pharmaceutical expenditure is directly contributing to the marketplace for novel treatments aimed at congenital disorders. Further entry points in this regard are being provided by the government support programs for rare diseases and interventions into the earliest stages in creating a viable ecosystem for diagnosing and treating congenital anomalies.

The congenital anomalies treatment market in Canada is growing due to increased government financing for health infrastructures and initiatives for better maternal and child health outcomes. According to a report by the World Health Organization in 2025, life expectancy at birth in Canada has improved by 2.4 years, from 79.1 to 81.6, reflecting improvements in early diagnosis and effective treatment of various illnesses, including congenital anomalies. This improvement brings on positive changes with improved healthcare services and further supports the need for newer treatments targeting congenital anomalies. With increasing awareness among healthcare professionals and parents regarding early intervention options, there is consequently a large demand for such specialized treatment all over the country.

Prevalence of Selected Congenital Anomalies (per 10,000 births) (2023)

Anomaly Type

Rate (per 10,000)

Trend

Neural tube defects

4.8

Stable

Genital anomalies

68.0

Stable

Congenital heart defects

20.8

Stable

Limb deficiency defects

4.0

Stable

Oro-facial clefts

15.8

Stable

Diaphragmatic hernia

3.1

Stable

Abdominal wall defects

5.8

Decreasing

Gastrointestinal defects

14.2

Stable

Chromosomal defects

18.0

Stable

CNS defects

5.3

Decreasing

Urinary tract defects

13.8

Increasing

Sense organ defects

4.9

Stable

Source: Government of Canada

Asia Pacific Market Insights

The congenital anomalies treatment market in the Asia Pacific is anticipated to capture the fastest-growing market by the end of 2035 due to increasing healthcare and pharmaceutical investments, technological advancements, and rising disease occurrence. According to a report by OECD in November 2022, average neonatal mortality in the lower-middle and lower-income economy nations in the region still stands high at 15.8 deaths per 1,000 live births. These points point toward the beauty challenges that indicate the urgent need for basic and advanced healthcare treatments and infrastructure. With most countries creating and expanding prenatal screening programs, fair optimism exists regarding an upward growth trajectory of this market, which is further promoted through investments in modern medical equipment.

The congenital anomalies treatment market in India is projected to register the fastest growth rate during the forecast period. This is primarily driven by supportive government policies and initiatives. As per a report by Invest India in May 2025, the medical devices sector size in India is expected to be around USD 14 billion, and is expected to increase to USD 30 billion by 2030. India has the fourth-largest medical device market in Asia after Japan, China, and South Korea, and one of the world's top 20 medical device markets. After that, the expanding consciousness of congenital disorders and infrastructural growth for healthcare in urban and rural settings keep up the demand for modern treatment modalities throughout the country.

The congenital anomalies treatment market in China is increasing due to growing government support for healthcare innovation, rising birth defect awareness, and expanding access to specialized medical care. As per a report by NLM in April 2023, the Center for Drug Evaluation (CDE) published and disseminated over  100 consultation drafts for drug R&D guidelines in 2022, marking the ramp-up in China for fast-tracking development and approval of innovative therapies, some of which are for rare or congenital disorders. The wave of regulations, in addition to the great investments made into pediatric healthcare and prenatal diagnostics, is ushering in higher rates of early detection and treatment for congenital anomalies across the country.

Europe Market Insights

The market in Europe is experiencing steady growth, advanced healthcare, and regulatory systems, in addition to higher investments in medical technologies. However, as per a report by OECD in December 2022, screening rates for breast cancer and cervical cancer dropped by 6%, on average, across the countries, signifying gaps in preventive care services. Besides, the document below summarizes the characteristics of the overall region's 14 congenital anomaly registers, along with national coverage that has been extracted from the National Congenital Anomaly Registers dataset. It includes coding systems, surveillance practices, pregnancy outcomes, and registry details, which are aligned with EUROCAT and ICBDSR standards.

European Congenital Anomalies Registers with National Coverage, January 10, 2020

Country

Registry Name

Year Created

Type

Network

Births (thousands, % coverage)

Compulsory

Time Limit

Anomaly Type

Coding

Pregnancy Outcomes

Surveillance

Czech Republic

National Registry of Congenital Anomalies (NRCA)

1964

Population

ICBDSR, EUROCAT

110 (100%)

Yes

15 years

–

ICD

Live birth, Stillborn, TOPFA

Yes

Denmark

Danish Medical Birth Registry

1973

Population

–

–

–

1 year

–

ICD

Live birth, Stillborn, TOPFA

–

England

NCARDRS

2015

Population

BINOCAR, ICBDSR

610 (100%)

No

–

Major, minor

ICD

Live birth, Stillborn, TOPFA

–

Finland

Register of Congenital Malformations

1963

Population

ICBDSR, EUROCAT

60 (100%)

Yes

1 year

Major

ICD

Live birth, Stillborn, TOPFA

Yes

Hungary

Hungarian Congenital Abnormality Registry (HCAR)

1962

Population

ICBDSR, EUROCAT

100 (100%)

Yes

1 year

Major, minor

ICD (modified)

Live birth, Stillborn, TOPFA

–

Latvia

Register of Patients Suffering from Certain Diseases

1987

Population

EUROCAT

19.2 (100%)

Yes

18 years

–

–

Live birth, Stillborn, TOPFA

–

Malta

Malta Congenital Anomalies Register (MCAR)

1985

Population

ICBDSR, EUROCAT

4 (100%)

No

1 year

Major, minor

ICD

Live birth, Stillborn

–

Norway

Medical Birth Registry of Norway (MBRN)

1967

Population

ICBDSR, EUROCAT

60 (100%)

Yes

1 year

–

ICD-BPA

Live birth, Stillborn, TOPFA

Yes

Poland

Polish Registry of Congenital Malformations (PRCM)

1997

Population

EUROCAT

300 (85%)

Yes

2 years

Major, minor

ICD

Live birth, Stillborn, TOPFA

Yes

Portugal

Portuguese National Registry of Congenital Anomalies (RENAC)

1995

Population

EUROCAT

–

No

Neonatal period

Major

ICD

Live birth, Stillborn, TOPFA

Yes

Scotland

Scottish Linked Routine Data Congenital Anomaly Register

2018

Population

EUROCAT

50-55 (100%)

Hybrid

1 year

Major

ICD

Live birth, Stillborn, TOPFA

–

Slovakia

Teratologic Information Centre, Slovak Medical University

1964

Population

ICBDSR

55 (100%)

Yes

Hospital-based

–

–

Live birth, Stillborn, TOPFA

–

Sweden

Swedish Medical Birth Registry (MBR)

1964

Population

ICBDSR, EUROCAT

100-120 (100%)

Yes

1 year

–

ICD

Live birth, Stillborn, TOPFA

Yes

Wales

Congenital Anomaly Register & Information Service for Wales (CARIS)

1998

Population

BINOCAR, ICBDSR, EUROCAT

35 (100%)

No

1 year

Major, minor

ICD

Live birth, Stillborn, TOPFA

–

Source: Scielosp, January 2020

The congenital anomalies treatment market in the UK is expected to grow due to the advancements in early diagnostics, pediatric care, and surgical innovations. According to a report by ONS in May 2024, in 2023, the entire healthcare expenditure grew by 5.6% in nominal terms, showing that economic pressures impacted the spending from a real-term perspective. The UK continues to direct investment towards critical health services, including terms such as maternal and neonatal health. Increasing weightage on genetic screening programs and NHS initiatives for early detection, intervention, and treatment of congenital disorders will contribute toward maintaining the demand for advanced treatment solutions in the coming years.

The market in Germany is expected to grow due to strong government initiatives to improve maternal and child health, along with ongoing R&D investments. As per a report by the World Health Organization in 2024, in 2022, Germany spent about 12.7% of its GDP on health. The government promotes early diagnosis through prenatal screening programs carried out nationwide, and there are regulations to support access to specialized pediatric care. In addition, the strong R&D landscape provides ample opportunities for public and private companies to innovate gene therapy, regenerative medicine, and advanced surgical techniques, thereby carving out enhanced treatment modalities for congenital anomalies.

Target Diseases of Neonatal Screening in Germany, Their Prevalence, and Their Year of Inclusion in The National Screening Program (2022)

Disease

Classification

Prevalence

Very-long-chain-acyl-CoA-dehydrogenase deficiency (VLCAD)

Fatty acid oxidation disorder, a metabolic disease

1:75 562

Medium-chain acyl-CoA-dehydrogenase deficiency (MCAD)

Fatty acid oxidation disorder, a metabolic disease

1:10 086

Long-chain-3-OH-acyl-CoA-dehydrogenase deficiency (LCHAD)

Fatty acid oxidation disorder, a metabolic disease

1:141 824

Carnitine palmitoyl transferase 1 deficiency (CPT-1)

Carnitine cycle defect, metabolic disease

1:576 159

Carnitine palmitoyl transferase 2 deficiency (CPT-2)

Carnitine cycle defect, metabolic disease

Carnitine acylcarnitine translocase ‧deficiency (CACT)

Carnitine cycle defect, metabolic disease

Phenylketonuria (PKU) and hyperphenylalaninemia (HPA)

Amino acid metabolism disorder, metabolic disease

1:5 262

Maple syrup urine disease (MSUD)

Amino acid metabolism disorder, metabolic disease

1:170 714

Tyrosinemia type 1

Amino acid metabolism disorder, metabolic disease

1:135 000*2

Glutaraciduria type 1 (GA1)

Metabolic disease, organoacidopathy

1:139 675

Isovaleric acidemia (IVA)

Metabolic disease, organoacidopathy

1:89 500

Biotinidase deficiency

Metabolic disease

1:28 365

Galactosemia

Carbohydrate metabolism disorder, metabolic disease

1:76 821

Primary hypothyroidism

Endocrinopathy

1:3 338

Adrenogenital syndrome (AGS)

Endocrinopathy

1:14 917

Cystic fibrosis (CF)

Lung disease

1:5 400*1

Severe combined immunodeficiency (SCID)

Immune disease

1:32 500*2

5q-associated spinal muscular atrophy (SMA)

Muscular disease

  

Sickle cell disease (SCD)

Hematological disease

  

Total

  

1:1 333

Source: NIH

Congenital Anomalies Treatment Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Key Congenital Anomalies Treatment Market Players:

    The congenital anomalies treatment market is highly competitive as the major global healthcare companies are on a flight for strategic initiatives to dent one another's market share. Some key players competing in the global congenital anomalies treatments market include Medtronic plc, Johnson & Johnson (Ethicon), Siemens Healthineers, Abbott Laboratories, and Boston Scientific. Through mergers and acquisitions, these companies seek to diversify their product lines and enhance their capabilities in the treatment of complex congenital abnormalities. Research, development, and deployment (RD&D) constitute the main thrust in this field, with enhanced investments being made in terms of advanced surgical tools, prenatal diagnostics, gene therapies, and minimally invasive procedures.

    Here is a list of key players operating in the global market:

    Company Name

    Country

    Market Share (2025)

    Medtronic plc

    Ireland

    16.2%

    Johnson & Johnson (Ethicon)

    U.S.

    13.1%

    Siemens Healthineers

    Germany

    11.2%

    Abbott Laboratories

    U.S.

    10.3%

    Boston Scientific

    U.S.

    9.5%

    GE HealthCare

    U.S.

    xx%

    F. Hoffmann‑La Roche Ltd.

    Switzerland

    xx%

    Terumo Corporation

    Japan

    xx%

    B. Braun Melsungen AG

    Germany

    xx%

    Dr. Reddy’s Laboratories

    India

    xx%

    Samsung Medison

    South Korea

    xx%

    CSL Limited (CSL Behring)

    Australia

    xx%

    Sanofi S.A.

    France

    xx%

    Baxter International Inc.

    U.S.

    xx%

    Duopharma Biotech Berhad

    Malaysia

    xx%

    Sources: NLM, NIH, WHO, CDC, HRSA

    Below are the areas covered for each company in the congenital anomalies treatment market:

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis

Recent Developments

  • In December 2024, the U.S. FDA approved Crenessity (crinecerfont) in combination with glucocorticoids (steroids) to treat pediatric patients 4 years of age and older suffering from classic congenital adrenal hyperplasia. 
  • In November 2024, PTC Therapeutics received FDA approval for AADC Deficiency Gene Therapy. This is the first-ever U.S.-based approved drug that is directly administered to the brain. This revolutionary drug is designed to address both children and adult age groups.
  • Report ID: 2702
  • Published Date: Oct 06, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In 2026, the industry size of congenital anomalies treatment is estimated at USD 188.8 million.

Congenital anomalies treatment market size is valued at USD 179.5 million in 2025 and is projected to reach USD 283.2 million by the end of 2035, rising at a CAGR of 5.2% during the forecast period, i.e., 2026-2035.

North America market is expected to hold the highest market share of 39% by the end of 2035, largely due to the U.S. and Canada’s flourishing provincial initiatives to bridge the gaps between supply and demand.

The major players in the market are Medtronic plc, Johnson & Johnson (Ethicon), Siemens Healthineers, Abbott Laboratories, Boston Scientific, GE HealthCare, F. Hoffmann La Roche Ltd., Terumo Corporation, B. Braun Melsungen AG, Dr. Reddy’s Laboratories, Samsung Medison, CSL Limited (CSL Behring), Sanofi S.A., Baxter International Inc., Duopharma Biotech Berhad.

Congenital Anomalies Treatment Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos